Moderna TX Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| infectiousDisease | ×0.90 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Moderna TX Inc. concentrates its licensing activity in Other, InfectiousDisease, and RareDisease. Moderna TX Inc. pays a 0.90x discount to market median, with the strongest premiums in InfectiousDisease (0.90x). Their most common deal structure is Collaboration, with an average disclosed value of $688M. Most recent activity: 2025.
Premium by therapeutic area
How Moderna TX Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Moderna TX Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 2 | $108M | $1.0B |
| License | 1 | $4M | $4M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | — | Carisma Therapeutics Inc. | — | unknown | $4M | $4M |
| 2024 | mRNA Group 1 H5NX pandemic influenza vaccine | HHS/BARDA | H5NX pandemic influenza | preclinical | $176M | $176M |
| 2023 | LNP gene therapy delivery platform | Generation Bio Co. | phenylketonuria, wilson disease, and other rare and prevalent indications | discovery | $40M | $1.9B |
How this is computed
For each Moderna TX Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.902, clamped to [0.7, 1.5].